Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 391

1.

Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.

Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM.

J Clin Psychiatry. 2002 May;63(5):420-4.

PMID:
12019667
2.

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.

Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M.

Arch Gen Psychiatry. 2001 Oct;58(10):965-72.

PMID:
11576036
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
5.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
6.

Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB.

J Clin Psychiatry. 2003 Apr;64(4):451-8.

PMID:
12716249
7.

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr.

Am J Psychiatry. 1994 Jan;151(1):20-6.

PMID:
8267129
8.

Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1330-6. Epub 2007 Jun 12.

PMID:
17618026
9.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241
10.

Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.

Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE.

J Clin Psychiatry. 2002 Apr;63(4):345-8.

PMID:
12000209
11.

Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.

Breier A, Buchanan RW, Irish D, Carpenter WT Jr.

Hosp Community Psychiatry. 1993 Dec;44(12):1145-9.

PMID:
8132186
12.

The effects of clozapine on symptom clusters in treatment-refractory patients.

Abraham G, Nair C, Tracy JI, Simpson GM, Josiassen RC.

J Clin Psychopharmacol. 1997 Feb;17(1):49-53.

PMID:
9004057
13.

Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D.

Biol Psychiatry. 1998 Sep 15;44(6):475-82.

PMID:
9777179
14.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR.

Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.

PMID:
20399340
15.
16.

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY.

J Clin Psychiatry. 2001 Nov;62(11):878-83.

PMID:
11775047
17.

Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.

Henderson DC, Goff DC.

J Clin Psychiatry. 1996 Sep;57(9):395-7.

PMID:
9746446
18.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
19.

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D.

J Clin Psychiatry. 1998 Oct;59(10):521-7.

PMID:
9818633
20.

Clinical outcome to clozapine treatment in chronic psychiatric inpatients.

Advokat CD, Bertman LJ, Comaty JE Jr.

Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jan;23(1):1-14.

PMID:
10368852

Supplemental Content

Support Center